This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT05936151 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 146 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Overweight or Obesity; CKD; Type 2 Diabetes |
| Interventions | Retatrutide; Placebo |
| Start | Jul 20, 2023 |
| Primary completion | Oct 1, 2025 |
| Study completion | Oct 21, 2025 |
| Results posted | Not yet |
| Registry last updated | Nov 25, 2025 |
Compounds on this site that cite this trial
What the registry says the trial is about
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change from Baseline in Glomerular Filtration Rate (mGFR) | Baseline, Week 24 |
17 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
